欧洲抗风湿病联盟系统性红斑狼疮管理推荐:2023年更新
欧洲抗风湿病联盟工作组基于2018年1月至2022年12月的系统文献综述更新了系统性红斑狼疮管理推荐,形成5条总体原则和13条推荐,涵盖羟氯喹、糖皮质激素、免疫抑制剂、钙调磷酸酶抑制剂和生物制剂的使用,以及治疗策略、目标、反应评估、联合与序贯治疗和减量方案。
要点
- 羟氯喹推荐用于所有狼疮患者,目标剂量为5 mg/kg实际体重/天,需考虑个体复发和视网膜毒性风险。
- 糖皮质激素作为疾病活动期的桥接治疗,维持治疗应减至≤5 mg/天泼尼松等效剂量并尽可能停用。
- 应及时考虑免疫抑制剂和/或生物制剂以控制疾病并促进糖皮质激素减量/停用。
核心结论
- 更新推荐基于新证据和专家意见为系统性红斑狼疮管理提供共识指导。
研究设计与样本
- 国际工作组提出系统文献综述问题(2018年1月至2022年12月),经系列会议制定并最终确定声明,采用预设投票流程对每条总体原则和推荐进行投票,并分配证据等级和推荐强度。
主要发现
- 工作组就5条总体原则和13条推荐达成一致,涉及羟氯喹、糖皮质激素、免疫抑制剂(甲氨蝶呤、麦考酚酯、硫唑嘌呤、环磷酰胺)、钙调磷酸酶抑制剂(环孢素、他克莫司、伏环孢素)和生物制剂(贝利尤单抗、阿尼鲁单抗、利妥昔单抗)的使用。
- 还提供了关于治疗策略和治疗目标、反应评估、联合和序贯治疗以及减量治疗的建 议。
关键数值与推荐
- 羟氯喹推荐用于所有狼疮患者,目标剂量5 mg/kg实际体重/天,需考虑个体复发和视网膜毒性风险。
- 糖皮质激素用于疾病活动期的桥接治疗;维持治疗应减至≤5 mg/天(泼尼松等效)并尽可能停用。
- 应考虑及时启用免疫抑制剂(甲氨蝶呤、硫唑嘌呤、麦考酚酯)和/或生物制剂(阿尼鲁单抗、贝利尤单抗)以控制疾病并促进糖皮质激素减量/停用。
- 环磷酰胺和利妥昔单抗应分别考虑用于器官威胁性和难治性疾病。
- 对于活动性狼疮肾炎,推荐糖皮质激素、麦考酚酯或低剂量静脉环磷酰胺作为锚定药物,应考虑联合贝利尤单抗或钙调磷酸酶抑制剂(伏环孢素或他克莫司)作为附加治疗。
临床怎么用
- 羟氯喹推荐用于所有狼疮患者,目标剂量5 mg/kg实际体重/天,需考虑个体复发和视网膜毒性风险。
- 糖皮质激素作为桥接治疗用于疾病活动期,维持治疗应减至≤5 mg/天(泼尼松等效)并尽可能停用。
- 应考虑及时启用免疫抑制剂(甲氨蝶呤、硫唑嘌呤、麦考酚酯)和/或生物制剂(阿尼鲁单抗、贝利尤单抗)以控制疾病并促进糖皮质激素减量/停用。
- 环磷酰胺和利妥昔单抗应分别考虑用于器官威胁性和难治性疾病。
- 对于活动性狼疮肾炎,推荐糖皮质激素、麦考酚酯或低剂量静脉环磷酰胺作为锚定药物,应考虑联合贝利尤单抗或钙调磷酸酶抑制剂(伏环孢素或他克莫司)作为附加治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To update the EULAR recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence. METHODS: An international Task Force formed the questions for the systematic literature reviews (January 2018-December 2022), followed by formulation and finalisation of the statements after a series of meetings. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned, and participants finally provided their level of agreement with each item. RESULTS: The Task Force agreed on 5 overarching principles and 13 recommendations, concerning the use of hydroxychloroquine (HCQ), glucocorticoids (GC), immunosuppressive drugs (ISDs) (including methotrexate, mycophenolate, azathioprine, cyclophosphamide (CYC)), calcineurin inhibitors (CNIs, cyclosporine, tacrolimus, voclosporin) and biologics (belimumab, anifrolumab, rituximab). Advice is also provided on treatment strategies and targets of therapy, assessment of response, combination and sequential therapies, and tapering of therapy. HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual's risk for flares and retinal toxicity. GC are used as 'bridging therapy' during periods of disease activity; for maintenance treatment, they should be minimised to equal or less than 5 mg/day (prednisone equivalent) and, when possible, withdrawn. Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation. CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor drugs, and add-on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered. Updated specific recommendations are also provided for cutaneous, neuropsychiatric and haematological disease, SLE-associated antiphospholipid syndrome, kidney protection, as well as preventative measures for infections, osteoporosis, cardiovascular disease. CONCLUSION: The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.
引用
- Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024. PMID: 37827694. doi:10.1136/ard-2023-224762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。